PDF(Pubmed)
Abstract：
Targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), have revolutionized the treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC). However, the emergence of resistance to EGFR TKIs especially the third generation TKIs such as osimertinib remains a major clinical challenge. As a broader strategy for combating resistance, several clinical trials have explored the efficacy of immune checkpoint inhibitors (ICIs)+chemotherapy in EGFR-mutated NSCLC. Until now, the ORIENT-31 and IMpower150 trials suggested that ICIs+ chemotherapy may be more effective than chemotherapy alone after failure of EGFR-TKIs (although ORIENT-31 was negative for overall survival [OS] and IMpower150 was a subset analysis, so the study was not powered to detect a difference); however, the CheckMate-722 trial yielded disappointing results. Thus, the results of this global trial KEYNOTE-789 were highly anticipated.
摘要：
靶向治疗,如表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs），彻底改变了EGFR突变非小细胞肺癌（NSCLC）的治疗前景。然而,EGFRTKIs耐药的出现,特别是第三代TKIs如奥希替尼仍然是一个重大的临床挑战.作为一个更广泛的反抵抗战略,多项临床试验探讨了免疫检查点抑制剂(ICIs)+化疗在EGFR突变的NSCLC中的疗效.直到现在,ORIENT-31和IMpower150试验表明，ICIs+化疗在EGFR-TKIs失败后可能比单独化疗更有效（尽管ORIENT-31对总生存期[OS]呈阴性，IMpower150是一个子集分析，所以这项研究没有能力检测到差异)；然而，CheckMate-722试验结果令人失望.因此，KEYNOTE-789这项全球试验的结果备受期待.
